Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Posted: January 13, 2025 at 2:54 am

WOBURN, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.

Read the original post:
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Related Posts